AI uncovers hidden target: could a powerful drug shrink 'HER2-Null' breast tumors?
Disease control
Not yet recruiting
This trial is testing whether the drug trastuzumab deruxtecan (T-DXd) can help people with a certain type of advanced breast cancer. The study focuses on patients whose tumors were originally classified as HER2-null (no HER2 protein) but were re-scored as HER2-ultralow using arti…
Sponsor: Shuangyue Liu • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC